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Abstract: Non-pharmacological self-management interventions for chemotherapy-induced peripheral neurotherapy (CIPN) are of clinical interest; however, no systematic review has synthesized the
evidence for their use in people with advanced cancer. Five databases were searched from inception to February 2022 for randomized controlled trials assessing the effect of non-pharmacological
self-management interventions in people with advanced cancer on the incidence and severity of
CIPN symptoms and related outcomes compared to any control condition. Data were pooled with
meta-analysis. Quality of evidence was appraised using the Revised Cochrane Risk of Bias Tool
for Randomized Trials (RoB2), with data synthesized narratively. Grading of Recommendations,
Assessment, Development and Evaluations (GRADE) was applied to assess the certainty of the
evidence. Thirteen studies were included, which had a high (69%) or unclear (31%) risk of bias.
Greatest confidence was found for physical exercise decreasing CIPN severity (SMD: −0.89, 95% CI:
−1.37 to −0.41; p = 0.0003; I2 = 0%; n = 2 studies, n = 76 participants; GRADE level: moderate) and
increasing physical function (SMD: 0.51, 95% CI: 0.02 to 1.00; p = 0.04; I2 = 42%; n = 3 studies, n = 120;
GRADE level: moderate). One study per intervention provided preliminary evidence for the positive
effects of glutamine supplementation, an Omega-3 PUFA-enriched drink, and education for symptom
self-management via a mobile phone game on CIPN symptoms and related outcomes (GRADE: very
low). No serious adverse events were reported. The strongest evidence with the most certainty
was found for physical exercise as a safe and viable adjuvant to chemotherapy treatment for the
prevention and management of CIPN and related physical function in people with advanced cancer.
However, the confidence in the evidence to inform conclusions was mostly very low to moderate.
Future well-powered and appropriately designed interventions for clinical trials using validated
outcome measures and clearly defined populations and strategies are warranted.

iations.
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1. Introduction
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Chemotherapy is a commonly used treatment in the advanced stages of cancer as a
cancer control strategy, where improvements to symptom management, quality of life, and
survival are prioritized [1,2]. However, chemotherapy is often associated with debilitating
side effects such as chemotherapy-induced peripheral neuropathy (CIPN), which can lead
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to suboptimal treatment regimens due to dose reductions or early cessation if the side
effects are severe [3]. CIPN, in particular, is highly prevalent and clinically problematic,
occurring in up to 60–80% of people receiving chemotherapy [3] as a consequence of neurotoxic damage to the structure and function of peripheral sensory, motor, and autonomic
nerves causing peripheral neuropathic symptoms [4]. Greater risk and severity of CIPN is
associated with higher doses and longer exposures to neurotoxic chemotherapies, which
are characteristic of advanced solid and hematological cancer treatment regimens [3,5].
Sensory CIPN symptoms in the hands and feet are the most common and include pins
and needles, pain, hypersensitivity, numbness, itchiness, and hot or cold sensations [6].
Motor CIPN symptoms comprise muscle weakness, wasting, or cramps, as well as impaired
motor skills and reflexes, and autonomic CIPN symptoms include gastroparesis as well as
cardiac, urogenital, and sexual dysfunction [6]. The severity of CIPN symptoms usually
declines after chemotherapy cessation but can also be long-lasting; the pooled prevalence
of CIPN symptoms following oxaliplatin treatment for colorectal cancer at 6, 12, 24 and
36 months after chemotherapy completion has recently been reported as 60%, 45%, 30%, and
25%, respectively [7]. Furthermore, people with advanced cancer often have continuous
chemotherapy cycles where acute or chronic CIPN is experienced, which presents a unique
challenge for this population. Symptoms of CIPN can negatively affect sleep, mood,
mobility, activities of daily living, and lead to distress, anxiety, depression, financial toxicity,
difficulty feeding, constipation and diarrhea, which further compromise cancer treatment
outcomes and quality of life [7–11].
Despite the high prevalence and significant patient and healthcare burden of CIPN,
treatment options are limited [3,10,11]. In the most recent 2020 clinical practice guidelines
for CIPN developed by the American Society of Clinical Oncology (ASCO) [12] and the
European Society for Medical Oncology (ESMO) [13], no recommendations were made
for preventing CIPN, and the use of duloxetine was the only treatment described as having some evidence to support its use for reducing neuropathic pain. Despite limited
supporting evidence, other pharmacological treatments used in practice include anticonvulsants (e.g., gabapentin/pregabalin), tricyclic antidepressants (e.g., amitriptyline), opioids
(e.g., oxycodone), as well as topical lidocaine [4,13–15]. Pharmacological interventions
target neuropathic pain, which is just one of a cluster of symptoms associated with CIPN [6].
In addition to lack of efficacy and narrow scope of use, pharmaceutical therapies used
for CIPN are associated with unfavorable side effects, such as nausea, dizziness, and
drowsiness, and include problematic outcomes of polypharmacy interactions with other
medications commonly prescribed in advanced cancer due to multimorbidity [4,14]. These
toxicities lead to prolonged infusion times, chemotherapy dose reductions, and treatment
cessation, which has negative impacts on treatment efficacy and reduces the quality of
life [12]. Unsurprisingly, non-pharmacological self-management interventions are of growing interest in assisting in the prevention and management of CIPN [14,16].
Non-pharmacological interventions are generally not first-line therapies for CIPN;
however, there is emerging evidence to support their early use [13,16]. A recent systematic review of 24 controlled trials determined non-pharmacological interventions to be
more effective than pharmacological treatments in managing Paclitaxel-induced peripheral
neuropathy symptoms in people diagnosed with any cancer or stage [14]. Specifically,
beneficial effects on CIPN symptoms were described for Chinese herbal medicine, acupuncture, exercise, vitamin E and Omega-3 polyunsaturated fatty acid (PUFA) supplementation,
massage, and foot baths [16]. ESMO Guidelines [13] recommend physical exercise as the
only non-pharmacological therapy with Level 1 quality evidence for effectively treating
neuropathic pain. However, insufficient evidence was available to make strong recommendations, with clinical trials and systematic reviews mostly of poor quality and that did not
consider advanced cancer [16].
Non-pharmacological interventions for CIPN that can be self-administered are of
particular interest, as symptom self-management strategies are often effective in achieving
improved wellbeing, quality of life, self-efficacy, a broader reach of health services, and
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cost savings in people with cancer [17–19]. Self-management strategies can be initiated
independently from an internal decision (e.g., massage) or with support from a health
professional (e.g., an exercise program) but include only those interventions that the patient
is responsible for administering (i.e., not acupuncture) [20,21]. To date, no systematic reviews or clinical guidelines have assessed non-pharmacological self-management strategies
specifically for advanced cancer patients, where chemotherapy use and CIPN is common,
co-morbidities are high, and daily functioning and overall quality of life are often more
valued than enhanced treatment outcomes or survival [22].
Therefore, in people with advanced cancer, this systematic review and meta-analysis
of randomized controlled trials sought to determine the effect of non-pharmacological
self-management interventions on the incidence and severity of CIPN symptoms and
CIPN-related outcomes (quality of life, physical function, sleep, fatigue, gastrointestinal
symptoms, nutrition status, psychosocial and financial outcomes, and adverse effects)
compared to any control condition.
2. Materials and Methods
This systematic review and meta-analysis is registered with the International Prospective Register of Systematic Reviews (PROSPERO ID: 308341) and reported according to
the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [23].
MEDLINE (Ovid), Embase, Web of Science, CINAHL (EBSCOhost), and Cochrane
CENTRAL databases were searched from inception to 7 February 2022 using keywords and
controlled vocabulary terms (Supplementary Table S1) based on the following: (“nonpharmacological intervention” AND “chemotherapy-induced peripheral neuropathy”
AND (“advanced cancer” OR “metastatic cancer”) AND “randomi?ed controlled trial”). To
identify relevant articles not found in the other databases, the first 200 records as sorted by
relevance ranking were taken from Google Scholar on 7 February 2022 [24]. A snowballing
technique was also used, whereby Google Scholar, database search updates, and reference
lists of included studies and relevant literature were assessed to find additional studies not
located in the original search strategy up until 5 April 2022.
Automated de-duplication of articles and manual text-mining [25] was conducted
by one investigator (MC) using Endnote software (EndNote 20, Clarivate, Version 20.2,
London, UK, 2021). During text-mining, irrelevant terms were searched in titles and abstracts to identify studies for exclusion such as ‘systematic review’, ‘protocol’, ‘mice’,
‘conference’, and ‘medication’ [25]. Screening of remaining titles, abstracts and full texts
was then completed by two investigators independently (MC and (PMY or AS or OAA))
using Covidence software (Covidence Systematic Review Software, Veritas Health Innovation, Version, Melbourne, Australia, 2021). Screening conflicts were resolved by discussion
among the investigators. Studies examining the effect of any non-pharmacological selfmanagement intervention on incidence or severity of CIPN symptoms in people with
advanced cancer were included. Advanced cancer was defined as any hematological cancer
or any solid tumor with locally or systemically advanced disease (The Union for International Cancer Control Tumor, Nodes, and Metastases Classification of Malignant Tumors
(UICC TNM) Stage of III-IV or equivalent) [26]. Self-management strategies were defined
as interventions that were administered by the person with cancer or their caregivers,
including those initiated with support from a health professional as well as initiated independently [20,21]. Eligibility criteria is presented in Table 1. The primary outcomes were
the incidence and severity of CIPN symptoms as measured by any tool at any timepoint.
Secondary outcomes were chosen based on existing literature on the factors related to
CIPN, including quality of life, physical function, sleep, fatigue, gastrointestinal symptoms,
nutrition status, psychosocial and financial outcomes, and adverse effects measured using
any tool at any timepoint.
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Table 1. Eligibility criteria for studies assessing the effect of non-pharmacological self-management
interventions on chemotherapy-induced peripheral neuropathy symptoms and related outcomes in
people with advanced cancer.
Inclusion Criteria

•
Population

•
•

Advanced cancer: any solid tumor with locally
or systemically advanced disease stage (UICC
TNM stage III–IV) [26] or any
hematological cancer 1
Undergoing or have undergone chemotherapy
Any age (i.e., adults and children)

Exclusion Criteria

•

Studies including people at any cancer
stage where results have not been reported
separately for those with advanced cancer

•

Pharmacological interventions (e.g.,
prescribed and non-prescribed medications)
Eligible non-pharmacological interventions
administered in conjunction with
pharmacological interventions for CIPN
(e.g., duloxetine, gabapentin, pregabalin,
carbamazepine, amitriptyline)
Non-pharmacological interventions not
administered by the person with cancer
(e.g., acupuncture, electrical nerve
stimulation, scrambler therapy,
moxibustion, reflexology,
intravenous vitamins)

•
•
Intervention

Comparator
Outcomes

Any non-pharmacological self-management
intervention administered by the person with
cancer or their caregiver (e.g., exercise, oral
nutrition supplements, massage, thermal
therapies, meditation), including those initiated
with support from a health professional

•

Any control (e.g., placebo, usual care)

•

Incidence or severity of CIPN symptoms as
measured by any tool

Study design

•
•

Randomized controlled parallel trials
Published in peer-reviewed journals

Language

•

English or able to be translated into English

•

•
•
•

Conference abstracts only
Non-randomized controlled trials
Narrative/systematic reviews, qualitative
studies, protocols, case studies,
observational studies

UICC TNM: The Union for International Cancer Control Tumor, Nodes, and Metastases Classification of Malignant
Tumors. 1 Studies that referred to ‘advanced cancer’ but do not specify the stage and/or type of cancer were
eligible for inclusion.

Data pertaining to study, participant, and intervention characteristics, as well as outcomes of interest, were extracted independently by one investigator (MC) and checked for
accuracy by a second investigator (OAA). Where outcome data were missing or incompletely reported, investigators contacted the authors via email. Individual study quality
assessment was conducted independently by two investigators (MC and OAA) using the
Revised Cochrane Risk of Bias Tool for Randomized Trials (RoB2) [27]. The RoB2 comprises
five domains with an overall risk of bias judgment calculated as low risk of bias, some
concerns, or high risk of bias [27]. Disagreements in data extraction and quality assessment
were managed by discussion among investigators.
Certainty in the body of evidence was determined using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach [28] via GRADEpro
GDT software (GRADEpro Guideline Development Tool, McMaster University and Evidence Prime, 2021). Four levels of certainty for the estimated effect of each outcome were
possible: very low (very little confidence in estimated effect), low (limited confidence),
moderate (moderately confident), and high (very confident) [28].
Where two or more studies reported the same intervention and sufficient incidence
or mean and variance data for the same outcome, data were pooled by meta-analysis
using Review Manager (RevMan) software [RevMan Software, The Cochrane Collaboration, Version 5.4.1, The Cochrane Collaboration, Oxford, UK, 2020]). Using the standard
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random effects method, categorical outcomes were reported as odds ratios (OR) using the
Mantel–Haenszel test, and continuous variables were pooled using the inverse variance
test and reported as mean differences (MD), where the same tool and scale were used, or
standardized mean differences (SMD), where different measurement tools or scales for the
same outcome were used. Interpretation of effects sizes for SMDs was: 0.2 represents a
small effect, 0.5 a moderate effect, and 0.8 a large effect [29]. Heterogeneity was evaluated
with the I2 statistic, whereby >50% represented substantial heterogeneity [30]. The cut-off
for statistical significance was considered at a p-value of <0.05. Results were synthesized in
tabular and narrative format.
3. Results
3.1. Search Results and Study Quality
Thirteen studies [31–43] published between 2014 and 2020 were included (Figure 1).
As indicated in Figure 2, 62% of studies had high risk of bias [32,33,35–37,39,40,42] and the
remaining 38% had unclear risk of bias [31,34,38,41,43]. One main reason for bias was the
lack of outcome assessor blinding and the use of subjective outcome measurement tools
that could have influenced outcome assessment due to the knowledge of the intervention
received. However, this is an acknowledged limitation in most exercise, diet, and lifestyle
research [44]. Other common sources of potential bias were the lack of information regarding allocation concealment procedures, failure to consider missing data with methods
such as intention-to-treat and imputation, selective outcome reporting, and inadequate
reporting of whether the study was conducted in accordance with a retrospective protocol.
Publication bias was unable to be assessed due to the small number of studies in each
meta-analysis. GRADE level of evidence for all outcomes was very low to low.

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) diagram
for selecting studies that examined the effect of non-pharmacological self-management interventions
on chemotherapy-induced peripheral neuropathy symptoms and related outcomes in people with
advanced cancer.
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Figure 2. The Revised Cochrane Risk of Bias Tool for Randomized Trials (RoB2) assessment
of studies that examined the effect of non-pharmacological self-management interventions on
chemotherapy-induced peripheral neuropathy symptoms and related outcomes in people with
advanced cancer [31–43].

3.2. Study Samples
Characteristics of the 13 studies are summarized in Table 2 and detailed in Supplementary Table S2. Study samples ranged from n = 27 [36] to n = 200 [35], representing a
total sample of N = 1012 participants [31–43]. One study comprised pediatrics [35], while
the remaining studies focused on adults only [31–34,36–43]. The majority of studies (85%)
included patients with advanced solid tumors [31,32,34,36–43], most of which (46%) had
colorectal cancer [34,36,38–41]. Most studies (92%) included patients undergoing active
chemotherapy [31–33,35–43], and the remaining study (8%) [34] included those undergoing
or who completed chemotherapy. Of the 12 studies (92%) that reported chemotherapy type,
all used neurotoxic agents [31,33–43] and all of the seven studies (54%) that reported CIPN
history only included participants with no existing CIPN [32,35,36,38–41].
3.3. Intervention Characteristics
Four studies (31%) examined physical exercise interventions (strength, endurance,
and sensorimotor training (n = 2) [33,34], strength and endurance training (n = 1) [31], and
walking (n = 1) [32]); four studies (31%) assessed nutrition supplements (glutamatic acid
(n = 1) [35], glutamine (n = 1) [38], curcumin (n = 1) [36], and Omega-3 PUFA-enriched
nutrition drink (n = 1) [37]); three studies (23%) explored orally consumed Japanese herbal
medicine (Goshajinkigan (n = 2) [40,41] and ninjin’yoeito (n = 1) [39]); and two studies
(15%) assessed technology-facilitated education for symptom self-management (education
for self-management via automated telephone voice technology incorporating symptom
monitoring (n = 1) [42] and education for symptom self-management via a mobile phone
game (n = 1) [43]). Comparator groups included standard care (55%) [31–33,36,38–40],
placebo (15%) [35,41], written information (15%) [34,43], or an active control (15%) [37,42].
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Table 2. Summary of characteristics and findings of studies that examined the effect of non-pharmacological self-management interventions on chemotherapyinduced peripheral neuropathy symptoms and related outcomes in people with advanced cancer.

+

+

o

o

o

Standard care
(n = 22)

Tuning fork
test; pre and
post (6 and
12 wks)

o

Standard care
(n = 31)

Tuning fork
test; pre and
post (12, 24 and
36 wks)

o

o

Adverse Events

+

Financial

+

Treatment

GI Symptoms

EORTC
QLQ-LC13; pre
and post (C3)

Social

Fatigue

Standard care
(n = 21)

Psychological

Tool and Time
Point

Nutrition Status

Control

Sleep

Intervention

Pain

CTX

CIPN-Related Outcomes
Physical Function

Cancer

CIPN
Quality of Life

Population

Findings

Severity

Citation
and
Country

Intervention Characteristics

Incidence

Study and Population Characteristics

Physical exercise

Henke
2014 [31];
Germany

N: 46
Age (yrs):
NR
Males: NR

Type: lung
Stage: ≥3
Existing
CIPN: NR

Type:
Platinum-based
Frequency: NR
Duration: NR
Status: ongoing

Stuecher
2019 [32];
Germany

N: 44
Age (yrs):
67 ± 8
Males: 67%

Type: gastrointestinal
Stage: ≥3
Existing
CIPN: no

Type: NR
Frequency: NR
Duration: NR
Status: ongoing

N: 61
Streckmann
Age (yrs):
2014 [33];
46 (19–73)
Germany
Males: 77%

Type:
lymphoma
Stage:
progressive
Existing
CIPN: NR

Type: mixed
Frequency: NR
Duration: NR
Status: ongoing

Strategy: Strength and
endurance training
(n = 25)
Regimen: 8 min
endurance or 3 sets of
4 strength exercises daily
Duration: 3 CTX cycles,
from C1D1
Strategy: Walking
(n = 22)
Regimen: 150 min
per wk
Duration: 12 wks,
from C1D1
Strategy: Strength,
endurance, and
sensorimotor training
(n = 30)
Regimen: 1 h session
twice per wk
Duration: 36 wks

+

+

o

+

o

+

o

+

+

+

o

+

+

o
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Written
exercise
guidelines
(n = 13)

FACT/GOGNTX; pre and
post (8 and
12 wks)

N: 200
Age (yrs):
9±5
Males: 62%

Type:
lymphoma
Stage: NR
Existing
CIPN: no

Type: Vincristine
Frequency:
weekly
Duration:
≥4 wks
Status: ongoing

Placebo
(n = 99)

mBPSPN; pre
and post
(5 wks)

o

N: 27
Age (yrs):
68 (53–78)
Males: NR

Type:
colorectal
Stage:
metastatic
Existing
CIPN: no

Type: 5FU and
oxaliplatin
Frequency:
fortnightly
Duration:
≤12 cycles
Status: ongoing

Standard care
(n = 9)

EORTC-QLQC30 and
NCI-CTAE; pre
and post

-

+

o

+

o

o

o

o

o

Adverse Events

Strategy: Strength,
endurance, and
sensorimotor training
(n = 17)
Regimen: 1 hr session
twice per wk
Duration: 8 wks

Financial

Type: mixed
Frequency: NR
Duration:
2–3 cycles
Status: ongoing
and ceased

Treatment

N: 30
Age (yrs):
50–81
Males: 70%

Type:
colorectal
Stage: 4
Existing
CIPN: NR

Social

Tool and Time
Point

Psychological

Control

Nutrition Status

Intervention

GI Symptoms

CTX

Fatigue

Cancer

Sleep

Population

Pain

CIPN-Related Outcomes
Physical Function

CIPN
Quality of Life

Zimmer
2018 [34];
Germany

Findings

Severity

Citation
and
Country

Intervention Characteristics

Incidence

Study and Population Characteristics

o

Nutrition supplements
Bradfield,
2015 [35];
USA

Howells,
2019 [36];
UK

Strategy: L-glutamic
acid in capsule form,
taken orally (n = 101)
Regimen: 3 times daily,
total 0.75–1.5 g per day
Duration: 5 wks
Strategy: Curcumin
powder in capsule form,
taken orally (n = 18)
Regimen: 4 times daily,
total 2 g per day
Duration: duration of
CTX (from 7 days
before C1D1)

o

o

o

-

o

+

o
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Wang,
2007 [38];
Taiwan

+

+

+

+

Adverse Events

NCI-CTCAE;
pre and post
(C1–C8)

+

Financial

Standard care
(n = 26)

o

Treatment

+

o

Social

Standard care
(n = 44)

NCI-CTCAE
and
Electrophysiological
exam; pre and
post (C2, C4
and C6)

+

Psychological

Type:
colorectal
Stage: 3
Existing
CIPN: no

Type:
capecitabine and
oxaliplatin
Frequency: every
3 wks
Duration:
8 cycles
Status: ongoing

EORTC-QLQC30 and -LC13;
pre and post
(C1 and C2)

Nutrition Status

Type: 5FU and
oxaliplatin
Frequency: every
4 wks
Duration: NR
Status: ongoing

Isocaloric diet
(n = 58)

GI Symptoms

N: 86
Age (yrs):
60% ≥50
Males: 65%

Type:
colorectal
Stage:
metastatic
Existing
CIPN: no

Tool and Time
Point

Fatigue

Type: NSCL
Stage: ≥3 b
Existing
CIPN: NR

Strategy: omega 3
(EPA)-enriched oral
nutrition supplement +
isocaloric diet (n = 54)
Regimen: 2 237 mL
drinks per day (provides
2.2 g EPA)
Duration: 2 CTX cycles,
from C1D1
Strategy:
Levo-Glutamine, taken
orally (n = 42)
Regimen: twice daily,
total 30 g per day for
7 days every 2 wks
Duration: 6 cycles,
from C1D1

Control

Sleep

N: 112
Age (yrs):
18–80
Males: 47%

Type: paclitaxel
and cisplatin/carboplatin
Frequency: every
wks
Duration:
2–6 cycles
Status: ongoing

Intervention

Pain

CTX

CIPN-Related Outcomes
Physical Function

Cancer

CIPN
Quality of Life

SanchezLara,
2014 [37];
Mexico

Population

Findings

Severity

Citation
and
Country

Intervention Characteristics

Incidence

Study and Population Characteristics

o

o

+

o

+

o

Japanese herbal medicine

Motoo
2020 [39];
Japan

N: 52
Age (yrs):
35–79
Males: 60%

Strategy: ninjin’yoeito
powder 1 , taken orally
(n = 26)
Regimen: 2–3 times
daily, total 9 g per day
Duration: 8 cycles,
from C1D1

o

o

o
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Niskioka,
2011 [40];
Japan

Oki, 2015
[41];
Japan

Given,
2008 [42];
USA

N: 47
Age (yrs):
≥21
Males: 0%

Type: breast
Stage:
metastatic
Existing
CIPN: NR

Type: mixed
Frequency: NR
Duration: NR
Status: ongoing

11-point Likert
scale; pre and
post (10 and
16 wks)

?

?

?

?

Adverse Events

Cognitive
behavioral
nurseadministered
telephone
symptom
management
(n = 23)

o

o

o

o

o

+

o

?

?

Technology-facilitated education for symptom self-management
Strategy: Education for
symptom
self-management via
automated telephone
voice technology
incorporating symptom
monitoring (n = 24)
Regimen: weekly phone
calls for 4 wks, then at
wk 6 and wk 8
Duration: 8 wks

Financial

-

Treatment

Placebo
(n = 93)

NCI-CTCAE
and DEB-NTC;
pre and post
(at each
CTX cycle)

Social

+

Psychological

DEB-NTC; pre
and post (at
each CTX
cycle)

Nutrition Status

Type: 5FU and
oxaliplatin
Frequency: every
2 wks
Duration:
12 cycles
Status: ongoing

Standard care
(n = 23)

GI Symptoms

N: 186
Age (yrs):
61 ± 11
Males: 55%

Type:
colorectal
Stage: 3
Existing
CIPN: no

Strategy:
Goshajinkigan 2 , taken
orally (n = 22)
Regimen: 2–3 times
daily, total 7.5 g per day
Duration: entire CTX
course (4–32 cycles),
from C1D1
Strategy:
Goshajinkigan 2 , taken
orally (n = 93)
Regimen: daily with
meals, total 7.5 g per day
Duration: entire CTX
course (12 cycles),
from C1D1

Tool and Time
Point

Fatigue

Type: 5FU and
oxaliplatin
Frequency: every
2 wks
Duration:
4–32 cycles
Status: ongoing

Control

Sleep

N: 45
Age (yrs):
48–80
Males: 49%

Type:
colorectal
Stage:
metastatic
Existing
CIPN: no

Intervention

Pain

CTX

CIPN-Related Outcomes
Physical Function

Cancer

CIPN
Quality of Life

Population

Findings

Severity

Citation
and
Country

Intervention Characteristics

Incidence

Study and Population Characteristics

?
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Table 2. Cont.

-

-

-

o

+

Adverse Events

+

Financial

+

Treatment

NCI-CTCAE;
pre and post
(3 wks)

Social

Symptom
management
booklet (n = 40)

Nutrition Status

Type: mixed
Frequency: NR
Duration: NR
Status: ongoing

Strategy: Education for
symptom
self-management via a
mobile phone game
(n = 36)
Regimen: >30 min per
day, 3 times per wk
Duration: 3 wks

GI Symptoms

Tool and Time
Point

Fatigue

Control

Sleep

Intervention

Pain

CTX

Psychological

Type: breast
Stage: 4
Existing
CIPN: NR

CIPN-Related Outcomes
Physical Function

N: 76
Age (yrs):
51 ± 7
Males: 0%

Cancer

CIPN
Quality of Life

Kim, 2018
[43];
Korea

Population

Findings

Severity

Citation
and
Country

Intervention Characteristics

Incidence

Study and Population Characteristics

o

1

Contains 12 crude Japanese herbs: Rehmannia root, Angelica root, Atractylodes rhizome, Poria Sclerotium, Ginseng, Cinnamon bark, Polygala root, Peony root, Citrus Unshiu
peel, Atsragalus root, Glycyrrhiza, Schisandra fruit. 2 Contains 10 crude Japanese herbs: Rehmannia root, Achyranthes root, Cornus fruit, Dioscorea rhizome, Plantago seed, Alisma
Rhizome, Poria Sclerotium, Moutan bark, Cinnamon bark, and aconite root.
. Statistically significant positive effect favoring intervention.
. Statistically significant negative
effect favoring control. . No statistically significant effect.
. Statistical significance not tested. 5FU: Fluorouracil; C: chemotherapy cycle; CIPN: chemotherapy-induced peripheral
neuropathy; CTX: chemotherapy; D: day; DEB-NTC: Neurotoxicity Criteria of Debiopharm; EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire; EORTC QLQ-LC13: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13; EPA: eicosapentaenoic acid;
FACT/GOG-NTX: Functional Assessment of Cancer Therapy Gynecologic Oncology Group Neurotoxicity; GI: Gastrointestinal; hr: hour; min: minutes; mBPSPN: Modified Balis
Pediatric Scale of Peripheral Neuropathies; NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; NSCL: non-small cell lung cancer; NR: not
reported; UK: United Kingdom; USA: United States of America; wk: week; yrs: years.
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3.4. Effect on CIPN Symptoms and Related Outcomes
Six studies (46%) [31,32,34,39–41] were analyzed in 18 meta-analyses. Table 3 summarizes meta-analysis results, and forest plots for non-significant findings are presented in
Supplementary Figures S1–S3. Justifications for GRADE ratings are given in Supplementary
Table S3.
Table 3. Results from meta-analyses that were conducted to evaluate the effect of nonpharmacological self-management interventions on chemotherapy-induced peripheral neuropathy
symptoms and related outcomes in people with advanced cancer.

Outcome

Pooled Estimate

Significance
of Pooled
Estimate

Heterogeneity

Number of
Studies
(Citations)

Sample
Size

GRADE
Level of
Evidence

Physical exercise
CIPN severity
Quality of life
Physical function
Endurance
Emotional wellbeing
Social wellbeing

SMD: −0.89,
95% CI: −1.37, −0.41
SMD: 0.47,
95% CI: 0.01, 0.93
SMD: 0.51,
95% CI: 0.02, 1.00
SMD: 1.11,
95% CI: −0.65, 2.87
SMD: 0.21,
95% CI: −0.42, 0.83
SMD: −0.02,
95% CI: −0.53, 0.50

p = 0.0003

0%

p = 0.05

0%

p = 0.04

42%

p = 0.22

93%

p = 0.52

45%

p = 0.95

21%

p = 0.68

92%

p = 0.71

85%

p = 0.31

80%

p = 0.31

89%

p = 0.37

70%

p = 0.66

30%

p = 0.13

0%

p = 0.54

0%

2
[31,34]
2
[31,34]
3
[31,32,34]
2
[31,34]
2
[31,34]
2
[31,34]

76

Moderate

76

Very low

120

Moderate

76

Very low

76

Very low

76

Very low

226

Very low

226

Very low

271

Very low

271

Very low

238

Very low

283

Very low

283

Very low

231

Very low

Japanese herbal medicine
CIPN incidence
- Grade 1
CIPN incidence
- Grade 2
CIPN incidence
- Grade 3
CIPN incidence
- Grade 2 and 3
Fatigue
Nausea
Vomiting
Diarrhoea

OR: 1.98,
95% CI: 0.08, 48.14
OR: 0.64,
95% CI: 0.06, 6.71
OR: 0.37,
95% CI: 0.05, 2.52
OR: 0.23,
95% CI: 0.01, 3.89
OR: 0.40,
95% CI: 0.06, 2.93
OR: 0.80,
95% CI: 0.28, 2.23
OR: 0.63,
95% CI: 0.34, 1.16
OR: 1.20,
95% CI: 0.67, 2.17

2
[39,41]
2
[39,41]
3
[39–41]
3
[39–41]
2
[39,41]
3
[39–41]
3
[39–41]
2
[40,41]
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Table 3. Cont.

Outcome

Anorexia
Relative dose
intensity of
oxaliplatin
Side effect:
Neutropenia
Side effect:
Thrombocytopenia

Pooled Estimate

Significance
of Pooled
Estimate

Heterogeneity

Number of
Studies
(Citations)

Sample
Size

GRADE
Level of
Evidence

OR: 0.71,
95% CI: 0.39, 1.27

p = 0.25

0%

3
[39–41]

283

Very low

SMD: 1.77,
95% CI: −1.13, 4.68

p = 0.23

98%

2
[39,41]

238

Very low

p = 0.30

0%

283

Very low

p = 0.14

0%

238

Very low

OR: 0.74,
95% CI: 0.41, 1.31
OR: 1.52,
95% CI: 0.87, 2.67

3
[39–41]
2
[39,41]

3.4.1. Physical Exercise
Incidence of CIPN was significantly lower with a strength, endurance, and sensorimotor training program in comparison to standard care (n = 1 study [33]; n = 61 participants
with lymphoma; GRADE level: very low). Severity of CIPN was significantly less with
strength and endurance training with or without sensorimotor training when compared to
standard care or written exercise guidelines via meta-analysis (SMD: −0.89, 95% CI: −1.37
to −0.41; p = 0.0003; I2 = 0%; n = 2 studies [31,34], n = 76 participants with lung or colorectal
cancer; GRADE level: moderate; Figure 3).

Figure 3. Severity of CIPN was significantly less and physical function was significantly higher with
physical exercise compared to standard care or written exercise guidelines in people with advanced
lung or gastrointestinal cancer (GRADE level: moderate) [31,32,34].

Physical function was significantly higher with exercise (strength and endurance
training with or without sensorimotor training, or walking) when compared to standard
care or written exercise guidelines via meta-analysis (SMD: 0.51, 95% CI: 0.02 to 1.00;
p = 0.04; I2 = 42%; n = 3 studies [31,32,34], n = 120 participants with lung or gastrointestinal
cancer; GRADE level: moderate; Figure 3). Quality of life [31] and emotional wellbeing [33]
were significantly higher with exercise in one of three studies (33%), but no significant
effect was found with meta-analysis (n = 76 participants with lung or colorectal cancer;
GRADE level: very low). Significant improvements in pain [31], sleep [33], fatigue [33],
diarrhea [33], and financial problems [33] were found with exercise in one of two studies
(50%), but data were unable to be pooled by meta-analysis (n = 107 participants with
lymphoma or lung cancer; GRADE level: very low). One study found improvements in
nutrition status and lean body mass with walking (n = 44 participants with gastrointestinal
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cancer; GRADE level: very low). No serious adverse events were reported with exercise
interventions [32–34].
3.4.2. Nutrition Supplements
Incidence of CIPN was significantly lower with glutamine supplementation compared
to standard care (n = 1 study [38]; n = 86 participants with colorectal cancer; GRADE
level: very low), whereas participants prescribed curcumin had a significantly higher
incidence of CIPN in comparison to standard care (n = 1 study [36]; n = 27 participants with
colorectal cancer; GRADE level: very low). CIPN severity was significantly lower with
consumption of an Omega-3 PUFA-enriched nutrition drink on an isocaloric diet compared
to an isocaloric diet alone (n = 1 study [37]; n = 112 participants with lung cancer; GRADE
level: very low).
Quality of life and incidence of chemotherapy dose reduction was significantly improved with glutamine consumption compared to standard care (n = 1 study [38];
n = 86 participants with colorectal cancer; GRADE level: very low). Fatigue severity,
appetite loss, and body weight maintenance were significantly improved with the consumption of an Omega-3 PUFA-enriched drink on an isocaloric diet compared to an isocaloric
diet alone (n = 1 study [37]; n = 112 participants with lung cancer; GRADE level: very low).
Curcumin supplementation was associated with a significantly higher cancer treatment
response rate and length of survival but also led to a significantly increased incidence of
diarrhea (n = 1 study [36]; n = 27 participants with colorectal cancer; GRADE level: very
low). No serious adverse events were reported with nutrition supplements [36–38].
3.4.3. Japanese Herbal Medicine
The incidence of CIPN was significantly reduced with the consumption of Japanese
herbal medicine in two studies [39,40], while the remaining study [41] found a significantly
increased incidence with the intervention. However, when meta-analyzed, Japanese herbal
medicine had no significant association with the likelihood of CIPN of Grade 1, 2, 3 or
≥2 (n = 3 studies [39–41]; n = 283 participants with colorectal cancer; GRADE level: very
low). Sensitivity analysis according to the type of herbal supplement (Goshajinkigan
vs. ninjin’yoeito) did not result in significant findings.
Relative dose intensity of oxaliplatin was significantly higher with consumption of
Japanese herbal medicine in two [39,41] of three studies [39–41]; however, there was
no significant effect with meta-analysis (n = 2 studies [39,41]; n = 238 participants with
colorectal cancer; GRADE level: very low). No serious adverse events were reported with
the consumption of Japanese herbal medicine [39–41].
3.4.4. Technology-Facilitated Education for Symptom Self-Management
The incidence of CIPN was significantly lower in participants who received education
for symptom self-management via a mobile phone game in comparison to a symptom
management booklet (n = 1 study [43]; n = 76 participants with breast cancer; GRADE
level: very low). Time to CIPN symptom response was lower in participants who received
education via automated telephone voice technology incorporating symptom monitoring
compared to cognitive-behavioral nurse-administered symptom management via telephone (35 vs. >55 days); however, statistical significance was not tested (n = 1 study [42];
n = 47 participants with breast cancer; GRADE level: very low).
Quality of life and medication compliance was significantly higher in participants who
received education for symptom self-management via a mobile phone game in comparison
to a symptom management booklet; however, results for physical function, nausea, and
psychological health favored the control (n = 1 study [43]; n = 76 participants with breast
cancer; GRADE level: very low). No serious adverse events were reported [43].
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4. Discussion
This systematic review is the first to synthesize evidence on the non-pharmacological
self-management interventions for CIPN and related outcomes in people with advanced
cancer. The strongest evidence was found for physical exercise with medium to large
beneficial effects on CIPN severity and physical function in adults, with moderate certainty
in the estimated effect size [31,34]. Some evidence with very low certainty in the effect,
and supported by one study only, was found in adults for the positive effects of glutamine
supplementation on CIPN incidence, quality of life, and incidence of chemotherapy dose
reduction [38]; an Omega-3 PUFA-enriched nutrition drink for CIPN severity, fatigue,
appetite loss, and body weight maintenance [37]; and a symptom self-management mobile
phone game for CIPN incidence, quality of life, and medication compliance [43]. Findings
are inconclusive as to whether CIPN symptoms are improved by glutamatic acid supplementation in children [35] and curcumin supplementation [36], Japanese herbal medicine
consumption [39–41], and an automated telephone symptom management system [42]
in adults. There were no serious adverse events reported with any non-pharmacological
self-management interventions [31–43].
Most evidentiary support exists for physical exercise for CIPN in people with advanced cancer, which has also been reported in the general cancer population. This is
consistent with the findings from a recent systematic review [45] of 16 physical exercise
interventions for CIPN in people at any stage of cancer, where exercise also improved physical function. The present review found additional benefits of exercise on CIPN symptom
severity, which is unique to our review and perhaps unique to people with advanced cancer,
and was not a finding in the general cancer population [45]. These beneficial effects of
exercise on CIPN are supported by mechanistic studies. For example, exercise counteracts
the deleterious effects of chemotherapy on the nervous system central to CIPN by reducing
inflammation, suppressing pain pathways, and enhancing neuroprotective factors involved
in the development, survival, and function of neurons [46,47]. In addition, exercise has
broader health benefits for people with advanced cancer, such as improved quality of life,
fatigue, body composition, psychosocial function, and sleep quality, and it appears safe
when implemented on advice from a health professional [48]. Although strong recommendations cannot be made with the available evidence for the use of exercise for CIPN
symptoms and related outcomes, it appears to be a safe, cost-effective, and viable adjuvant
to chemotherapy to promote general health and wellbeing as well as CIPN prevention and
management. Future well-powered randomized controlled trials are needed to confirm the
efficacy and determine optimal exercise regimens, including exercise type and frequency,
which is largely heterogeneous in the existing literature.
An emerging area of research for the prevention and management of CIPN in advanced
cancer is the use of nutritional supplements. Consistent with the findings of this review, a
recent meta-analysis in the general cancer population found that participants consuming
Omega-3 PUFA supplements were 80% less likely to experience CIPN [49]. However,
the findings of our current review were based on a study supplementing Omega-3 PUFA
in an oral nutrition supplement drink [37]. Therefore, it cannot be confirmed whether
the beneficial effects on CIPN resulted from Omega-3 PUFA or one or a combination of
other nutrients with known benefits on nerve functioning and suggested modest benefits
on CIPN in other cancer populations, such as amino acids, B vitamins, vitamin E, and
magnesium [16,50–52]. Our current review did find additional potential benefits of the
amino acid glutamine for CIPN in advanced cancer populations [38]. Elsewhere, a review
of five studies found oral glutamine to benefit neuropathic pain in participants with cancer
of any stage; however, the clinical efficacy of glutamine for CIPN was judged to be unable
to justify the additional daily cost [53]. Thus, future research on dietary interventions
should consider cost-effectiveness in conjunction with the efficacy of isolated compounds
and prioritize assessment of essential nutrients rather than non-nutrients such as curcumin
or Japanese herbal medicine, for which there is less convincing evidence. No clinical
recommendations can yet be made for nutrition supplements for CIPN in advanced cancer
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patients. However, clinical practice should focus on correcting nutritional deficiencies
prior to, during, and after chemotherapy, especially for the aforementioned nutrients with
suggested involvement in CIPN or biochemical parameters that have been found to be
deficient in those with CIPN, such as vitamin D, hemoglobin, and albumin [54,55].
Our review also suggests that technology could assist in the education for selfmanagement of CIPN. In the general cancer population, healthcare interventions delivered
via a mobile device (mHealth) have been associated with improved pain, fatigue, psychological distress, and sleep outcomes [56]. mHealth interventions have also shown
potential to reach a large population due to ease of access, resulting in economic benefits
to patients and healthcare systems [56]. In people with advanced cancer, improvements
in cancer-related pain were observed after mHealth enabled psychoeducation that would
otherwise only be accessible when implemented by a specialist [57]. Technology aside,
the research emphasizes the requirement for self-management strategies in people with
advanced cancer to be individualized and multi-faceted to consider older age, depression,
impaired physical functioning, and low literacy, which may lead to greater difficulty in
symptom self-management [17]. In addition, self-management strategies should be embedded within the person’s support network and include strong partnerships with healthcare
professionals, caregivers, and relatives [17]. Future research is warranted to determine the
key elements of self-management strategies and the potential role of technology to facilitate
implementation specifically for CIPN in people with advanced cancer.
Limitations and Future Research
Conclusions of this review have been drawn from a limited number of heterogeneous
studies, evident by most outcomes having a GRADE rating of very low. Reasons for
downgrading the level of evidence included substantial heterogeneity, small sample size,
inadequate blinding, unclear random allocation concealment, lack of intention-to-treat analysis, and selective outcome reporting. Sources of heterogeneity were varying chemotherapy
regimens, cancer types, and interventions, which were often reported with minimal detail.
Furthermore, CIPN assessment methods were mostly subjective, not always validated, and
differed greatly between the studies, which is problematic as a wide variation in CIPN
outcomes has been noted with different measurement tools [58]. This suggests that the
current tools measure different aspects of CIPN and thus might need to be implemented in
combination to gather an accurate evaluation of CIPN. In addition, this systematic review
was stringently conducted and reported according to best-practice guidelines [23,29] but
only included studies in English and, therefore, may not have captured valuable research
from some countries.
Future studies are needed to enhance the confidence in findings by increasing the
body of evidence as well as the quality of the conduct of research. Randomized controlled trials should be well-designed with prescriptive interventions that seek to establish
cause-effect and dose–response relationships. Randomized controlled trials should also
be well-powered and use validated outcome measures and blinding where possible. Data
should be reported in full and include adverse events, secondary outcomes related to CIPN,
and compliance with self-management interventions. In people with advanced cancer,
studies should prioritize exercise interventions and consider nutritional interventions and
interactive technology-facilitated education for self-management support strategies administered alone or in combination. Additional suggested areas of research include those which
have shown benefit in the general cancer population but are yet to be tested in advanced
cancer. This includes low-cost and easily accessible interventions of massage, heat therapy,
and meditation [20,59]. Future studies should also explore how non-pharmacological
self-management interventions may best be implemented in conventional cancer care.
5. Conclusions
The strongest evidence with the most certainty was found for physical exercise as a
safe and viable adjuvant to chemotherapy treatment for the prevention and management of
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CIPN and related physical function in people with advanced cancer. Nutrition supplements
of glutamine and an Omega-3 PUFA-enriched drink showed some benefit, and the use of
interactive technology may facilitate education for self-management of CIPN; however,
certainty of these effects was very low. The confidence in the evidence to inform conclusions
was mostly very low to moderate, which warrants future clinical trials. Trials should
be rigorously designed and reported to include adequate sample size, clearly defined
populations and interventions, and use valid outcome measures.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/nu14122403/s1, Table S1: Systematic search strategy to identify randomized controlled trials that examined the effect of non-pharmacological interventions on
chemotherapy-induced peripheral neuropathy symptoms and related outcomes; Table S2: Characteristics and findings of studies that examined the effect of self-administered non-pharmacological
interventions on chemotherapy-induced peripheral neuropathy symptoms and related outcomes;
Figure S1: Japanese herbal medicine had no significant association with the likelihood of CIPN of
Grade 1, 2, 3 or ≥2 (n = 2–3 studies; n = 226–271 participants; GRADE level: very low). Sensitivity
analysis according to the type of herbal supplement (Goshajinkigan vs. ninjin’yoeito) did not result in
significant findings; Figure S2: Physical exercise had no significant effect on quality of life, endurance,
and emotional or social wellbeing (n = 2 studies; n = 76 participants; GRADE level: very low);
Figure S3: Japanese herbal medicine had no significant effect on fatigue, nausea, vomiting, diarrhea,
anorexia, relative dose reduction in oxaliplatin, neutropenia, nor thrombocytopenia (n = 2–3 studies; n = 231–283 participants; GRADE level: very low); Table S3: Grading of Recommendations,
Assessment, Development and Evaluation (GRADE) for each outcome examining the effect of selfadministered non-pharmacological interventions on chemotherapy-induced peripheral neuropathy
symptoms and related outcomes.
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Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.;
Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019, 366, l4898. [CrossRef]
Guyatt, G.H.; Oxman, A.D.; Schuenemann, H.J.; Tugwell, P.; Knottnerus, A. GRADE guidelines: A new series of articles in the
Journal of Clinical Epidemiology. J. Clin. Epidemiol. 2011, 64, 380–382. [CrossRef]
Higgins, J.P.T.T.J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. Cochrane Handbook for Systematic Reviews of
Interventions Version 6.2 (Updated February 2021): Cochrane; John Wiley & Sons: Hoboken, NJ, USA, 2021; Available online:
https://www.training.cochrane.org/handbook (accessed on 20 March 2022).
Ryan, R. Heterogeneity and Subgroup Analyses in Cochrane Consumers and Communication Group Reviews: Planning the Analysis at
Protocol Stage; Cochrane Consumers and Communication Review Group: Melbourne, Australia, 2016.
Henke, C.C.; Cabri, J.; Fricke, L.; Pankow, W.; Kandilakis, G.; Feyer, P.C.; De Wit, M. Strength and endurance training in the
treatment of lung cancer patients in stages IIIA/IIIB/IV. Support. Care Cancer 2013, 22, 95–101. [CrossRef]
Stuecher, K.; Bolling, C.; Vogt, L.; Niederer, D.; Schmidt, K.; Dignaß, A.; Banzer, W. Exercise improves functional capacity and
lean body mass in patients with gastrointestinal cancer during chemotherapy: a single-blind RCT. Support. Care Cancer 2018, 27,
2159–2169. [CrossRef]
Streckmann, F.; Kneis, S.; Leifert, J.A.; Baumann, F.T.; Kleber, M.; Ihorst, G.; Herich, L.; Grüssinger, V.; Gollhofer, A.; Bertz, H.
Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann. Oncol.
2014, 25, 493–499. [CrossRef] [PubMed]

Nutrients 2022, 14, 2403

34.

35.
36.

37.

38.
39.

40.

41.

42.

43.
44.
45.
46.

47.

48.
49.

50.
51.

52.

53.
54.

55.

19 of 20

Zimmer, P.; Trebing, S.; Timmers-Trebing, U.; Schenk, A.; Paust, R.; Bloch, W.; Rudolph, R.; Streckmann, F.; Baumann, F.T.
Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance
and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support. Care Cancer 2017, 26, 615–624.
[CrossRef] [PubMed]
Bradfield, S.M.; Sandler, E.; Geller, T.; Tamura, R.N.; Krischer, J.P. Glutamic acid not beneficial for the prevention of vincristine
neurotoxicity in children with cancer. Pediatr. Blood Cancer 2014, 62, 1004–1010. [CrossRef] [PubMed]
Howells, L.M.; Iwuji, C.O.; Irving, G.R.B.; Barber, S.; Walter, H.; Sidat, Z.; Griffin-Teall, N.; Singh, R.; Foreman, N.; Patel, S.R.; et al.
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a
Randomized Phase IIa Trial. J. Nutr. 2019, 149, 1133–1139. [CrossRef]
Sánchez-Lara, K.; Turcott, J.G.; Juárez-Hernández, E.; Nuñez-Valencia, C.; Villanueva, G.; Guevara, P.; De la Torre-Vallejo, M.;
Mohar, A.; Arrieta, O. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical
outcomes in patients with advanced non-small cell lung cancer: RANDOMISED trial. Clin. Nutr. 2014, 33, 1017–1023. [CrossRef]
Wang, W.S.; Lin, J.K.; Lin, T.C.; Chen, W.S.; Jiang, J.K.; Wang, H.S.; Chiou, T.J.; Liu, J.H.; Yen, C.C.; Chen, P.M. Oral glutamine is
effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12, 312–319. [CrossRef]
Motoo, Y.; Tomita, Y.; Fujita, H. Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy
in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: A randomized, open-label, phase 2 trial
(HOPE-2). Int. J. Clin. Oncol. 2020, 25, 1123–1129. [CrossRef]
Nishioka, M.; Shimada, M.; Kurita, N.; Iwata, T.; Morimoto, S.; Yoshikawa, K.; Higashijima, J.; Miyatani, T.; Kono, T. The Kampo
medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int. J. Clin. Oncol. 2011, 16, 322–327.
[CrossRef]
Oki, E.; Emi, Y.; Kojima, H.; Higashijima, J.; Kato, T.; Miyake, Y.; Kon, M.; Ogata, Y.; Takahashi, K.; Ishida, H.; et al. Preventive
effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): A placebo-controlled, double-blind,
randomized phase III study. Int. J. Clin. Oncol. 2015, 20, 767–775. [CrossRef]
Given, C.W.; Sikorskii, A.; Tamkus, D.; Given, B.; You, M.; McCorkle, R.; Champion, V.; Decker, D. Managing Symptoms Among
Patients with Breast Cancer During Chemotherapy: Results of a Two-Arm Behavioral Trial. J. Clin. Oncol. 2008, 26, 5855–5862.
[CrossRef]
Kim, H.J.; Kim, S.M.; Shin, H.; Jang, J.-S.; Kim, Y.I.; Han, D.H. A Mobile Game for Patients with Breast Cancer for Chemotherapy
Self-Management and Quality-of-Life Improvement: Randomized Controlled Trial. J. Med. Internet Res. 2018, 20, e273. [CrossRef]
Mirmiran, P.; Bahadoran, Z.; Gaeini, Z. Common Limitations and Challenges of Dietary Clinical Trials for Translation into Clinical
Practices. Int. J. Endocrinol. Metab. 2021, 19, e108170. [CrossRef] [PubMed]
Guo, S.; Han, W.; Wang, P.; Wang, X.; Fang, X. Effects of exercise on chemotherapy-induced peripheral neuropathy in cancer
patients: A systematic review and meta-analysis. J. Cancer Surviv. 2022, 11. E-pub ahead of print. [CrossRef] [PubMed]
Chung, K.H.; Park, S.B.; Streckmann, F.; Wiskemann, J.; Mohile, N.; Kleckner, A.S.; Colloca, L.; Dorsey, S.G.; Kleckner, I.R.
Mechanisms, Mediators, and Moderators of the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy. Cancers
2022, 14, 1224. [CrossRef] [PubMed]
Brett Whalen, L.; Zachary Wright, W.; Kundur, P.; Angadi, S.; Modesitt, S.C. Beneficial effects of exercise on chemotherapy-induced
peripheral neuropathy and sleep disturbance: A review of literature and proposed mechanisms. Gynecol. Oncol. Rep. 2022,
39, 100927. [CrossRef] [PubMed]
Heywood, R.; McCarthy, A.L.; Skinner, T. Efficacy of Exercise Interventions in Patients with Advanced Cancer: A Systematic
Review. Arch. Phys. Med. Rehabil. 2018, 99, 2595–2620. [CrossRef] [PubMed]
Lam, C.N.; Watt, A.E.; Isenring, E.A.; De Van Der Schueren, M.A.E.; Van Der Meij, B.S. The effect of oral omega-3 polyunsaturated
fatty acid supplementation on muscle maintenance and quality of life in patients with cancer: A systematic review and metaanalysis. Clin. Nutr. 2021, 40, 3815–3826. [CrossRef]
Chen, J.; Shan, H.; Yang, W.; Zhang, J.; Dai, H.; Ye, Z. Vitamin E for the Prevention of Chemotherapy-Induced Peripheral
Neuropathy: A meta-Analysis. Front. Pharmacol. 2021, 12, 684550. [CrossRef]
Schloss, J.M.; Colosimo, M.; Airey, C.; Masci, P.; Linnane, A.W.; Vitetta, L. A randomised, placebo-controlled trial assessing the
efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Support. Care Cancer 2016, 25, 195–204. [CrossRef]
Wesselink, E.; Winkels, R.M.; van Baar, H.; Geijsen, A.J.M.R.; van Zutphen, M.; Van Halteren, H.K.; Hansson, B.M.E.; Radema, S.A.;
De Wilt, J.H.W.; Kampman, E.; et al. Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy
in Colorectal Cancer Patients. Nutrients 2018, 10, 39. [CrossRef]
Sun, W.-N.; Su, J.-W.; Shen, Z.-P.; Hsu, H.-T. Effect of Oral Glutamine on Chemotherapy-Induced Peripheral Neuropathy in
Cancer Patients: An Evidence-Based Appraisal. Hu li za zhi J. Nurs. 2018, 65, 61–69.
Jennaro, T.S.; Fang, F.; Kidwell, K.M.; Smith, E.M.L.; Vangipuram, K.; Burness, M.L.; Griggs, J.J.; Van Poznak, C.; Hayes, D.F.;
Henry, N.L.; et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res. Treat.
2020, 180, 707–714. [CrossRef] [PubMed]
Tofthagen, C.; Tanay, M.; Perlman, A.; Starr, J.; Advani, P.; Sheffield, K.; Brigham, T. A Systematic Review of Nutritional Lab
Correlates with Chemotherapy Induced Peripheral Neuropathy. J. Clin. Med. 2022, 11, 355. [CrossRef] [PubMed]

Nutrients 2022, 14, 2403

56.
57.

58.

59.

20 of 20

Hernandez Silva, E.; Lawler, S.; Langbecker, D. The effectiveness of mHealth for self-management in improving pain, psychological distress, fatigue, and sleep in cancer survivors: A systematic review. J. Cancer Surviv. 2019, 13, 97–107. [CrossRef]
Azizoddin, D.R.; Adam, R.; Kessler, D.; Wright, A.A.; Kematick, B.; Sullivan, C.; Zhang, H.; Hassett, M.J.; Cooley, M.E.;
Ehrlich, O.; et al. Leveraging mobile health technology and research methodology to optimize patient education and selfmanagement support for advanced cancer pain. Supportive Care Cancer 2021, 29, 5741–5751. [CrossRef]
Molassiotis, A.; Cheng, H.L.; Lopez, V.; Au, J.S.K.; Chan, A.; Bandla, A.; Leung, K.T.; Li, Y.C.; Wong, K.H.; Suen, L.K.P.; et al. Are
we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective,
multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19, 132. [CrossRef]
Oh, P.-J.; Kim, Y.L. Effectiveness of Non-Pharmacologic Interventions in Chemotherapy Induced Peripheral Neuropathy: A
Systematic Review and Meta-Analysis. J. Korean Acad. Nurs. 2018, 48, 123–142. [CrossRef]

